Wromedica I Bielicka A Strzalkowska s.c. — Clinical Trial Site

47 Registered trials

10 Currently recruiting

Organisation

Wromedica I Bielicka A Strzalkowska s.c.

Location

Wroclaw, Poland

Identifier

ORG-100039870

Address

Ul. Adama Mickiewicza 91, 51-685, Poland

Departments

#1706
#40095; Dermatology
#40095: Dermatology
#40095: nap
#5810
1702: Dermatology
2605
40095: WroMedica I. Bielicka A Strzalkowska s.c.
Dermatology
n.d.
N/A
N/A Private site
NA
Private Practice
Wromedica
Wromedica Centrum Zdrowia
Wromedica I Bielicka A Strzalkowska s.c.
WroMedica s.c

Clinical trials at this site (47)

Search interface

Study to Evaluate the Efficacy and Safety of ATI-045 in Atopic Dermatitis Not authorised

2024-520302-19-00 Atopic dermatitis 4
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
A study to evaluate the efficacy and safety of subcutaneous amlitelimab on background topical corticosteroids therapy in participants aged 1… Recruiting

2023-508099-12-00 Dermatitis atopic 5 2024-06-20
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-507039-39-00 Moderate to Severe Plaque Psoriasis 5 2024-03-22
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Moderate to Severe Plaque Psoriasis 5 2024-01-18
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Psoriatic Arthritis 5 2025-06-26
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects with Moderate to… Recruiting

2022-502519-13-00 Moderate to Severe Plaque Psoriasis 5 2021-05-07
A study to learn how the study drug bimekizumab works and how safe it is in treating moderate to severe hidradenitis suppurativa in children… Ended

2023-505323-31-00 Hidradenitis Suppurativa 5 2025-10-09
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT… Ended

2024-515523-11-00 Chronic Weight Management 5 2025-06-09
A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P55 with Cosentyx in Patients with Moderat… Ended

2024-513348-27-00 Plaque psoriasis 5 2025-05-09
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata Patients (Rezolve AA) Ended

2023-509981-39-00 Alopecia Areata 4 2024-11-20
A Phase 2b Study to Evaluate Eltrekibart in Adults with Moderate to Severe Hidradenitis Suppurativa Ended

2023-505608-43-00 Moderate to Severe Hidradenitis Suppurativa 4 2024-07-04
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended

2023-507456-69-00 Atopic Dermatitis 4 2024-04-25
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505120-59-00 Moderate to Severe Plaque Psoriasis 5 2023-12-19
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505122-34-00 Plaque Psoriasis 5 2023-12-05
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended

2023-504716-15-00 Psoriatic Arthritis 6 2021-08-06
Study to see how good and safe Tildrakizumab is in children aged 6 to under 18 years of age with skin patches Ended

2023-504447-14-00 Treatment of pediatric subjects with moderate to severe 10 2021-07-29